Articles related to KIDNEY CANCER/RCC
Adjuvant Pembrolizumab after Nephrectomy in Renal Cell Carcinoma
In the KEYNOTE-564 trial, adjuvant pembrolizumab demonstrated a significant improvement in disease-free survival among patients with renal-cell carcinoma at high risk of recurrence after nephrectomy, offering a new direction in post-surgical treatment strategies.
Nephrology February 20th 2024
Immunotherapy Post-Surgery Improves Overall Survival For Kidney Cancer
In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.
Oncology, Medical February 12th 2024
A Tale of Two ICIs: Adjuvant Pembro Ups Survival in RCC, Nivo Doesn’t
Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.
Oncology, Medical February 5th 2024
FDA Approves Kidney Cancer Therapy After Dana-Farber-Led Research Shows Improved Outcomes For Patients with Advanced Disease
Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.
Nephrology January 8th 2024
Fox Chase Cancer Center Study Challenges Assumptions About Cystic Renal Masses
A recent study from Fox Chase Cancer Center has revealed that as many as 23% of cystic renal masses may carry high-grade, or aggressive, disease. This finding challenges the prevailing assumption of their low-risk nature and underscores the need for more discerning diagnostic and treatment strategies.
Oncology, Medical November 6th 2023